Professor Thozhukat Sathyapalan

MBBS, MD, FRCP, FACP, FHEA

Chair in Academic Endocrinology, Diabetes and Metabolism / Honorary Consultant Physician

Role at Hull York Medical School

Thozhukat Sathyapalan (Sathya) is the Chair in Academic Diabetes, Endocrinology and Metabolism in Hull York Medical School, University of Hull and Honorary Consultant Endocrinologist at Hull and East Yorkshire Hospitals NHS Trust, UK. He obtained his undergraduate degree in Medicine from University of Kerala, India in 1996 and his MD (General Medicine) from JIPMER, India. He subsequently did his clinical training in Diabetes and Endocrinology as a Specialist Registrar in Yorkshire Deanery. Sathya was a Clinical Research Fellow in University of Hull and obtained his MD (Diabetes and Endocrinology) in 2009. He was appointed as Senior Lecturer in Hull York Medical School in October 2009, Reader in 2012 and was made Chair in Academic Endocrinology and Metabolism in 2016.

Biography
  • MBBS, Trivandrum Medical College, India 1990-1996
  • MD (General Medicine), JIPMER, India 1997-2000
  • Postgraduate Clinical Training (Grampian University Hospitals and Yorkshire Deanery) 2001-2009
  • Clinical Research Fellow, University of Hull 2006-2008
  • Senior Lecturer, Hull York Medical School 2009-2012
  • Reader, Academic Diabetes, Endocrinology and Metabolism 2013-2016
  • Chair, Academic Diabetes, Endocrinology and Metabolism 2016 -
Research

His main area of interest is on modulation of cardiovascular risk through pharmacological and nutritional interventions in insulin resistant states such as obesity, polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus.  He is interested in traditional as well as novel risk factors, specifically endocrine disruptors.

Teaching

Postgraduate (clinical)

  • Organise and lead the Continuing Medical Education programme for endocrine trainees and Consultants in Diabetes and Endocrinology for Health Education Yorkshire and the Humber. RCP-accredited. Delivered by national and international speakers.
  • Educational and Clinical Supervisor for Foundation year trainees, Core Medical trainees and Specialty Trainees in Endocrinology and diabetes

Undergraduate

  • Delivering plenary lectures for Hull York Medical School students
  • Phase II Student Selected Components (SSCs) on ‘patient pathway through research’
  • Critically appraised topic (CAT) assessment for Phase II students
  • Thyroid teaching clinics and diabetes teaching clinics for Hull York Medical School Year 4 students
  • Multi-disciplinary clinical teaching for Year 3 students: type 1 and type 2 diabetes, dedicated sessions with diabetes specialist nurses, podiatrists, and dieticians
  • OSLER and OSCE examiner for Hull York Medical School Year 4 and 5 medical students
Publications
  1. Papageorgiou M, Sathyapalan T, Schutte R. Muscle mass measures and incident osteoporosis in a large cohort of postmenopausal women. J Cachexia Sarcopenia Muscle. 2018.
  2. Deshmukh H, Papageorgiou M, Kilpatrick ES, Atkin SL, Sathyapalan T. Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018.
  3. Al-Qaissi A, Papageorgiou M, Javed Z, Heise T, Rigby AS, Garrett AT, et al. Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus. Diabetes Obes Metab. 2018.
  4. Reyes-Munoz E, Sathyapalan T, Rossetti P, Shah M, Long M, Buscema M, et al. Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review. Adv Ther. 2018;35(11):1805-15.
  5. Al-Qaissi A, Papageorgiou M, Deshmukh H, Madden LA, Rigby A, Kilpatrick ES, et al. Effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes. Diabetes Obes Metab. 2018.
  6. Sathyapalan T, Dawson AJ, Rigby AS, Thatcher NJ, Kilpatrick ES, Atkin SL. The Effect of Phytoestrogen on Thyroid in Subclinical Hypothyroidism: Randomized, Double Blind, Crossover Study. Front Endocrinol (Lausanne). 2018;9:531.
  7. Papageorgiou M, Wells L, Williams C, White KLM, De Santis B, Liu Y, et al. Occurrence of deoxynivalenol in an elderly cohort in the UK: a biomonitoring approach. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2018;35(10):2032-44.
  8. Heffernan AL, Cunningham TK, Drage DS, Aylward LL, Thompson K, Vijayasarathy S, et al. Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. Int J Hyg Environ Health. 2018;221(7):1068-75.
  9. Konya J, Spurgeon BEJ, Al Qaissi A, Sathyapalan T, Ajjan R, Madden L, et al. Corrigendum: The Effect of a Simulated Commercial Flight Environment With Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants With Type 2 Diabetes - A Cross-Over Study. Front Endocrinol (Lausanne). 2018;9:301.
  10. Alkandari A, Ashrafian H, Sathyapalan T, Sedman P, Darzi A, Holmes E, et al. Improved physiology and metabolic flux after Roux-en-Y gastric bypass is associated with temporal changes in the circulating microRNAome: a longitudinal study in humans. BMC Obes. 2018;5:20.
  11. Kahal H, Aburima A, Spurgeon B, Wraith KS, Rigby AS, Sathyapalan T, et al. Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes Metab. 2018;44(5):431-6.
  12. Sathyapalan T, Aye M, Rigby AS, Thatcher NJ, Dargham SR, Kilpatrick ES, et al. Soy isoflavones improve cardiovascular disease risk markers in women during the early menopause. Nutr Metab Cardiovasc Dis. 2018;28(7):691-7.
  13. Chattopadhyay S, George A, John J, Sathyapalan T. Adjustment of the GRACE score by 2-hour post-load glucose improves prediction of long-term major adverse cardiac events in acute coronary syndrome in patients without known diabetes. Eur Heart J. 2018;39(29):2740-5.
  14. Gonzalez S, Sathyapalan T, Javed Z, Atkin SL. Effects of Growth Hormone Replacement on Peripheral Muscle and Exercise Capacity in Severe Growth Hormone Deficiency. Front Endocrinol (Lausanne). 2018;9:56.
  15. Chattopadhyay S, George A, John J, Sathyapalan T. Correction to: Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol. 2018;55(5):459.
  16. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Keevil B, Atkin SL. Salivary and serum androgens with anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Sci Rep. 2018;8(1):3795.
  17. Konya J, Al Qaissi A, Sathyapalan T, Ajjan R, Madden L, Naseem KM, et al. The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes - A Cross-over Study. Front Endocrinol (Lausanne). 2018;9:26.
  18. Chattopadhyay S, George A, John J, Sathyapalan T. Two-hour post-challenge glucose is a better predictor of adverse outcome after myocardial infarction than fasting or admission glucose in patients without diabetes. Acta Diabetol. 2018;55(5):449-58.
  19. Papageorgiou M, Wells L, Williams C, White K, De Santis B, Liu Y, et al. Assessment of Urinary Deoxynivalenol Biomarkers in UK Children and Adolescents. Toxins (Basel). 2018;10(2).
  20. Sathyapalan T, Javed Z, Rigby AS, Kilpatrick ES, Atkin SL. Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. J Endocr Soc. 2017;1(5):423-30.
  21. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Atkin SL. Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018;88(2):258-62.
  22. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Kilpatrick ES, Atkin SL. Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - a randomised controlled study. Sci Rep. 2017;7(1):15366.
  23. O'Doherty AF, Jones HS, Sathyapalan T, Ingle L, Carroll S. The Effects of Acute Interval Exercise and Strawberry Intake on Postprandial Lipemia. Med Sci Sports Exerc. 2017;49(11):2315-23.
  24. Sathyapalan T, Coady AM, Kilpatrick ES, Atkin SL. The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. Endocr Connect. 2017;6(8):811-6.
  25. Gonzalez S, Windram JD, Sathyapalan T, Javed Z, Clark AL, Atkin SL. Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. J Int Med Res. 2017;45(6):1708-19.
  26. Sathyapalan T, Dickerson EH, Maguiness SM, Robinson J, Dakroury YHZ, Atkin SL. Androstenedione and testosterone levels correlate with in vitro fertilization rates in insulin-resistant women. BMJ Open Diabetes Res Care. 2017;5(1):e000387.
  27. Dawson AJ, Kilpatrick ES, Coady AM, Elshewehy AMM, Dakroury Y, Ahmed L, et al. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord. 2017;17(1):41.
  28. Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, et al. Deoxynivalenol Biomarkers in the Urine of UK Vegetarians. Toxins (Basel). 2017;9(7).
  29. Sathyapalan T, Al-Qaissi A, Kilpatrick ES, Dargham SR, Adaway J, Keevil B, et al. Salivary testosterone measurement in women with and without polycystic ovary syndrome. Sci Rep. 2017;7(1):3589.
  30. Cho LW, Sathyapalan T, Kilpatrick ES, Keevil BG, Miller AG, Coady AM, et al. Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome. BMC Endocr Disord. 2017;17(1):26.
  31. Sathyapalan T, Rigby AS, Bhasin S, Thatcher NJ, Kilpatrick ES, Atkin SL. Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism: A Randomized Controlled Study. J Clin Endocrinol Metab. 2017;102(2):425-33.
  32. Wells L, Hardie L, Williams C, White K, Liu Y, De Santis B, et al. Determination of Deoxynivalenol in the Urine of Pregnant Women in the UK. Toxins (Basel). 2016;8(11).
  33. O'Doherty AF, Sathyapalan T, Rigby AS, Ingle L, Carroll S. The repeatability of the abbreviated (4-h) Oral Fat Tolerance Test and influence of prior acute aerobic exercise. Eur J Nutr. 2018;57(1):309-18.
  34. Simintiras CA, Frohlich T, Sathyapalan T, Arnold GJ, Ulbrich SE, Leese HJ, et al. Modelling oviduct fluid formation in vitro. Reproduction. 2016.
  35. Sathyapalan T, Javed Z, Kilpatrick ES, Coady AM, Atkin SL. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;86(3):384-7.
  36. Greetham S, Goodwin S, Wells L, Whitham C, Jones H, Rigby A, et al. Pilot Investigation of a Virtual Gastric Band Hypnotherapy Intervention. Int J Clin Exp Hypn. 2016;64(4):419-33.
  37. Sathyapalan T, Aye M, Rigby AS, Fraser WD, Thatcher NJ, Kilpatrick ES, et al. Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial. J Bone Miner Res. 2017;32(1):157-64.
  38. Sathyapalan T, Dakroury Y, Ahmed L, Elshewehy AM, Kilpatrick ES, Coady AM, et al. Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016;85(4):671-3.
  39. Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv Endocrinol Metab. 2016;7(1):12-23.
  40. Javed Z, Qamar U, Sathyapalan T. Pituitary and/or hypothalamic dysfunction following moderate to severe traumatic brain injury: Current perspectives. Indian J Endocrinol Metab. 2015;19(6):753-63.
  41. Javed Z, Qamar U, Sathyapalan T. The role of kisspeptin signalling in the hypothalamic-pituitary-gonadal axis--current perspective. Endokrynol Pol. 2015;66(6):534-47.
  42. Sathyapalan T, David R, Gooderham NJ, Atkin SL. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. Sci Rep. 2015;5:16890.
  43. George A, Bhatia RT, Buchanan GL, Whiteside A, Moisey RS, Beer SF, et al. Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study. PLoS One. 2015;10(11):e0142045.
  44. Sathyapalan T, Thatcher NJ, Hammersley R, Rigby AS, Courts FL, Pechlivanis A, et al. Aspartame sensitivity? A double blind randomised crossover study. PLoS One. 2015;10(3):e0116212.
  45. Mellor DD, Sathyapalan T, Kilpatrick ES, Atkin SL. Diabetes and chocolate: friend or foe? J Agric Food Chem. 2015;63(45):9910-8.
  46. Sathyapalan T, Atkin SL, Kilpatrick ES. LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation. Ann Clin Biochem. 2015;52(Pt 1):180-2.
  47. Dawson AJ, Sathyapalan T, Sedman P, Ajjan R, Kilpatrick ES, Atkin SL. Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls. Obes Surg. 2014;24(3):349-58.
  48. Kamalanathan S, Sahoo JP, Sathyapalan T. Pregnancy in polycystic ovary syndrome. Indian J Endocrinol Metab. 2013;17(1):37-43.
  49. Dawson AJ, Sathyapalan T, Smithson JA, Vince RV, Coady AM, Ajjan R, et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;80(6):843-9.
  50. Dawson AJ, Sathyapalan T, Atkin SL, Kilpatrick ES. Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med. 2013;30(10):1172-80.
  51. Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes Obes Metab. 2013;15(8):767-9.
  52. Sathyapalan T, Shepherd J, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2012;97(11):3951-5.
  53. Sathyapalan T, Dixit S. Radiotherapy-induced hypopituitarism: a review. Expert Rev Anticancer Ther. 2012;12(5):669-83.
  54. Shor D, Sathyapalan T, Atkin SL, Thatcher NJ. Does equol production determine soy endocrine effects? Eur J Nutr. 2012;51(4):389-98.
  55. Sathyapalan T, Atkin SL. Recent advances in cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol. 2012;166(4):575-83.
  56. Dickerson EH, Sathyapalan T, Knight R, Maguiness SM, Killick SR, Robinson J, et al. Endocrine disruptor & nutritional effects of heavy metals in ovarian hyperstimulation. J Assist Reprod Genet. 2011;28(12):1223-8.
  57. Sathyapalan T, Smith KA, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Ann Clin Biochem. 2012;49(Pt 1):80-5.
  58. Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). 2012;76(2):196-200.
  59. Sathyapalan T, Aye MM, Atkin SL. Postural hypotension. BMJ. 2011;342:d3128.
  60. Thong KY, Jose B, Blann AD, Cull ML, Mills AP, Sathyapalan T, et al. Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Diabetes Res Clin Pract. 2011;93(2):e87-91.
  61. Wakil A, Sathyapalan T, Atkin SL. Pituitary hypophysitis and gulf war syndrome: a case series and hypothesis. Clin Endocrinol (Oxf). 2011;75(2):272-4.
  62. Sathyapalan T, Atkin SL. Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes? Minerva Endocrinol. 2011;36(2):147-56.
  63. Thong KY, Jose B, Sukumar N, Cull ML, Mills AP, Sathyapalan T, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes Obes Metab. 2011;13(8):703-10.
  64. Sathyapalan T, Manuchehri AM, Thatcher NJ, Rigby AS, Chapman T, Kilpatrick ES, et al. The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2011;96(5):1442-9.
  65. Kahal H, Atkin SL, Sathyapalan T. Pharmacological treatment of obesity in patients with polycystic ovary syndrome. J Obes. 2011;2011:402052.
  66. Dawson AJ, Mellor DD, Sathyapalan T, Kilpatrick ES, Atkin SL. Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. Diabet Med. 2011;28(1):124-5.
  67. Sathyapalan T, Beckett S, Rigby AS, Mellor DD, Atkin SL. High cocoa polyphenol rich chocolate may reduce the burden of the symptoms in chronic fatigue syndrome. Nutr J. 2010;9:55.
  68. Mellor DD, Sathyapalan T, Kilpatrick ES, Beckett S, Atkin SL. High-cocoa polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabetes patients. Diabet Med. 2010;27(11):1318-21.
  69. Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem. 2010;56(11):1696-700.
  70. Sathyapalan T, Atkin SL, Kilpatrick ES. Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. Diabetes Care. 2010;33(9):1948-50.
  71. Sathyapalan T, Atkin SL, Kilpatrick ES. Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement? Diabetes Obes Metab. 2010;12(6):540-4.
  72. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm. 2010;2010:758656.
  73. Sathyapalan T, Manuchehri AM, Rigby AS, Atkin SL. Subclinical hypothyroidism is associated with reduced all-cause mortality in patients with type 2 diabetes. Diabetes Care. 2010;33(3):e37.
  74. Sathyapalan T, Atkin SL. Evidence for statin therapy in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1(1):15-22.
  75. Sathyapalan T, Mellor D, Atkin SL. Obesity and gestational diabetes. Semin Fetal Neonatal Med. 2010;15(2):89-93.
  76. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010;72(4):566-8.
  77. Sathyapalan T, Gonzalez S, Atkin SL. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric. 2009;12(5):427-30.
  78. Sathyapalan T, Cho L, Kilpatrick ES, Le Roux CW, Coady AM, Atkin SL. Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2010;72(3):423-5.
  79. Sathyapalan T, Atkin SL. Investigating hirsutism. BMJ. 2009;338:b912.
  80. Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2009;70(1):124-8.
  81. Sathyapalan T, Atkin SL, Kilpatrick ES. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. Diabet Med. 2008;25(8):909-15.
  82. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab. 2009;94(1):103-8.
  83. Sathyapalan T, Cho LW, Kilpatrick ES, Coady AM, Atkin SL. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol (Oxf). 2008;69(6):931-5.
  84. Manuchehri AM, Sathyapalan T, Jayagopal V, Kilpatrick ES, Ghatei MA, Bloom SR, et al. Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations. Clin Endocrinol (Oxf). 2008;68(5):836-8.
  85. Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Pituitary. 2007;10(3):261-6.
  86. Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL. Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary. 2007;10(3):233-6.
  87. Mistry D, Maung KH, Manuchehri AM, Sathyapalan T, Atkin S, England J. Key developments in endocrinology. Practitioner. 2005;249(1673):541, 3-7, 9 passim.

 

Non indexed publications

  1. Crabtree TSJ, Wilmot E, Sathyapalan T 2018. Freestyle Libre: available on the NHS? The British Journal of Diabetes: 18:1
  2. Abiola D, Sathyapalan T, Hepburn D 2016 Management of type 1 and type 2 diabetes requiring insulin. Prescriber 27.09
  3. Mackenzie G, Boa AN, Taboada AD, Atkin SL, Sathyapalan T. 2015 Sporopollenin, the least known yet toughest natural biopolymer Mini Review, Front. Mater. - Polymer Chemistry. DOI: 10.3389/fmats.2015.00066
  4. Kadiyala P, Walton S, Sathyapalan T. 2015. Insulin induced lipodystrophy. Br J Diabetes Vasc Dis 2014;14:131-133.
  5. Sathyapalan T. 2015 The environmental obesogen hypothesis for diabesity.
Postgraduate research supervision

Katie Bird - Evaluation of pharmacology prescribing assessment for undergraduate medical students (Principal Supervisor)

Alexandra Macnamara - Evaluation of pharmacology teaching for undergraudate medical students (Principal Supervisor)

Dr Mo Aye – Hull Hip fracture Intervention and Prevention Programme (HHIPP) (PhD 2015-18) OSPREY – osteoporosis research charity. (Principal Supervisor)

Youssra HZ Dakroury - Vitamin D effects in Qatari population (MSc 2018-19), Weill Cornell at Qatar (Principal Supervisor)

Mr REJ England - Parameters for parathyroid surgery in hyperparathyroidism ( MD - 2018)

Saeed Alqarni - Endoparticle profile in patients with type 2 diabetes (PhD 2015-18) (Co-supervisor)

External roles

Administrative roles

  • Chair of Hull York Medical School Ethics committee (2016 - )
  • Lead the Academic Endocrinology, Diabetes and Metabolism Group at HYMS
  • Lead the Endocrinology Comprehensive Research Network for Yorkshire and Humber
  • Deputy lead for the Diabetes Comprehensive Research Network for Yorkshire and Humber.
  • Member of NIHR CRN national committee for metabolic and endocrine disorders.

National Committees

  • Association of British Clinical Diabetologists (ABCD) National Committee: 2013 – to date
  • National UK lead for Freestyle Libre audit
  • British Society for Endocrinology, National Clinical Committee: 2014 – 2018
  • UKI NETS Clinical Practice Committee: 2015 – to date
  • Member of European Neuroendocrine Tumour Society 2017 – to date
  • Steering Committee for the UK Acromegaly Register: 2016 – to date
  • National Institute of Health Research, Health Technology Assessment, Diagnostic Technologies & Screening Programmes (DTSP) Panel member: 2013-15
  • Member of Steering Group – ABCD Nationwide Exenatide/Liraglutide Audit: 2013-15
  • Member of Strategic Clinical Network Board (Diabetes), Yorkshire and Humber Group)
  • Member and key stakeholder in the Acne Priority Setting Partnership, James Lind Alliance.
  • Chairman of Pit Pat, Hull (local branch of Pituitary Foundation, patient support group, UK)

Membership of professional bodies

  • American College of Physicians
  • British Endocrine Society
  • American Endocrine Society
  • Royal College of Physicians (Edin)
  • Association of British Clinical Diabetologists
  • European neuroendocrine tumour society
  • Senior Fellow of Higher Education Academy

Editorial board

  • Scientific Reports (Nature Publishing Group)
  • Clinical Endocrinology
  • British Journal of Diabetes (Associate Editor)
  • Frontiers in Diabetes (Associate Editor)